for Tobramycin

Version: 0.95.5 beta / Built 20170531
Disclaimer:

TDMx has been created for personal use only. The use of any result generated by TDMx is in any case the sole risk and responsibility of the TDMx user. Therapeutic decision should not solely rely on TDMx as information provided by TDMx does not replace clinical judgement. Although TDMx has been validated carefully, there is no guarantee for the accuracy of the provided results.

When using TDMx, you automatically agree with this disclaimer and the legal notices!

All Rights Reserved, 2017

Dr. Sebastian G. Wicha

c/o University of Hamburg, Hamburg, Germany

Dr. Stefanie Hennig

Marc Burgard

c/o University of Queensland, Brisbane, Australia


Information to users:
This is a beta version! You can improve TDMx by reporting any bug/issue you observed! Just email us!
References
Population PK model (hospitalised patients): Hennig et al. Clin Pharmacokinet, 2013: 289-301

Powered by RStudio(TM)

R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
Demographics
Dose [mg] | Infusion dur. [h]
Laboratory

Serum creatinine [┬Ámol/L]

Measured tobramycin [mg/L]


Time [dd/mm/yyyy/hh:mm]

Dose [mg]

Infusion duration [h]

cTobramycin [mg/L]


Format/Unit

Time [dd/mm/yyyy/hh:mm]

Cmax/MIC [-]

Cmin [mg/L]

Infusion duration [h]

Probabilistic dosing scenarios (no drug measurements used/needed!)

        

Format/Unit

Time [dd/mm/yyyy/hh:mm]

Cmax/MIC [-]

Cmin [mg/L]

Infusion duration [h]

Prediction of next dose based on individual patient (using Bayesian estimates)

        
PK model

Warning: Modification of PK model recommended for research purposes only!

Residual unexplained variability (RUV):